Search hospitals > California > Santa Rosa
CCOP - Santa Rosa Memorial Hospital
Claim this profileSanta Rosa, California 95403
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Head and Neck Cancers
Conducts research for Non-Small Cell Lung Cancer
166 reported clinical trials
4 medical researchers
Summary
CCOP - Santa Rosa Memorial Hospital is a medical facility located in Santa Rosa, California. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Head and Neck Cancers, Non-Small Cell Lung Cancer and other specialties. CCOP - Santa Rosa Memorial Hospital is involved with conducting 166 clinical trials across 236 conditions. There are 4 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Breast Cancer
Global LeaderER positive
PR positive
HER2 negative
2Cancer
Global LeaderStage I
Stage II
HER2 positive
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
179 drugs studied
Charles W. DrescherProvidence Portland Medical Center7 years of reported clinical research
Expert in Cancer
Studies Tumors
47 reported clinical trials
96 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
26 reported clinical trials
63 drugs studied
Clinical Trials running at CCOP - Santa Rosa Memorial Hospital
Breast Cancer
Gallbladder Cancer
Pancreatic Cancer
Ovarian Tumors
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Adenocarcinoma
Ovarian Carcinoma
Small Intestinal Adenocarcinoma
Esophageal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CCOP - Santa Rosa Memorial Hospital?
CCOP - Santa Rosa Memorial Hospital is a medical facility located in Santa Rosa, California. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Head and Neck Cancers, Non-Small Cell Lung Cancer and other specialties. CCOP - Santa Rosa Memorial Hospital is involved with conducting 166 clinical trials across 236 conditions. There are 4 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.